Page 168 - CW E-Magazine (3-9-2024)

News from Abroad

EXPANDING CAPABILITIES
Fujifilm Diosynth Biotechnologies opens microbial

manufacturing facility in UK

Fujifilm Diosynth Biotechno-
logies – a part of diversified Japanese
conglomerate Fujifilm and a pharma
contract development and manufacturing
organisation (CDMO) – recently opened
its microbial fermentation manu-
facturing facility in Billingham, UK.

This new facility triples existing
microbial production throughput with
the addition of a new production line
equipped with 2 X 4,000-L fermenters,
primary separations suite and a modu-
lar purification suite with an investment
over 100 million GBP (around $130-mn).
To support further expansion, the faci- degeneration (AMD). Wet AMD is an Mr. Kenneth Bilenberg, the company’s
lity is built with the flexibility to eye disorder that causes blurred vision Chief Operations Officer, noted that the
accommodate new projects. in the central vision. “With the com- move underscores the firm’s commitment
pletion of this project, we are fulfilling to the BioCampus in Billingham where
The company said the expansion was our commitment with our partner, and “we are progressing on expansions for
customised, in part, to support an un- supporting the commercialization of its our process development and quality labs
named “large pharmaceutical partner” ophthalmic therapeutic,” said Mr. Lars as well as an expansion focusing on late
with a highly specialised ophthalmic Petersen, President and CEO, Fujifilm stage clinical and commercial cell culture
therapeutic for wet age-related macular Diosynth Biotechnologies. drug substance manufacturing.”

MULTIFUNCTIONAL PRESERVATIVES
Inolex files patent infringement lawsuit against Actera

Ingredients

US-based speciality chemicals firm, as blends comprising the CHA-diol of safe preservation, specifically un-
Inolex, has filed a patent infringement compositions. der the Spectrastat tradename family
complaint against Actera Ingredients of products. As a team of inventors and
in the US District Court for the District The lawsuit seeks permanent designers, Inolex takes a firm position
of Delaware in relation to the former’s injunctions against further infringe- in respecting the integrity of intellectual
multifunctional preservation technology ments, as well as monetary damages property,” said a company spokeswoman.
for personal care products. for sales of infringing products.
Inolex offers its portfolio of CHA-
As per the lawsuit Actera Ingre- Last year, Inolex asserted the same diol broad spectrum systems under the
dients infringed claims from two patents against AE Chemie in a US Spectrastat tradename. Using a hurdle
Inolex patents covering its preservation court, which resulted in a settlement on technology approach, Spectrastat employs
systems comprising caprylhydroxamic favourable terms for Inolex. an intelligent combination of different
acid (CHA) and select diols. The pat- preservation factors, or techniques, to
ents claim the use of these ingredient “Inolex has spent the past two deca- create multiple barriers to microbial
compositions in formulations as well des investing heavily in the innovation growth that inhibit microorganisms.

168 Chemical Weekly September 3, 2024

Contents Index to Advertisers Index to Products Advertised